Ribosomal protein L36a pseudogene 1 (RPL36AP1)

Ribosomal protein L36a pseudogene 1 (RPL36AP1) is classified as a processed pseudogene, meaning it is a non-functional genomic DNA sequence resembling the protein-coding gene ribosomal protein L36a (RPL36A). Pseudogenes do not code for a functional protein, though some may be transcribed into RNA and could participate in regulatory mechanisms such as RNA interference in certain contexts[1][8]. RPL36AP1 is not a canonical drug target and has no established role in disease, biomarker utility, or pharmacological interactions. Its gene status is approved with the locus type “pseudogene” by the HUGO Gene Nomenclature Committee[8]. Key clarifications: - RPL36AP1 is a pseudogene, *not* the functional RPL36A ribosomal protein or a pharmacological receptor, enzyme, or similar canonical drug target. - It is not currently considered directly relevant in biomarker panels, as a therapeutic target, or in drug safety assessments. - The confusion may arise because some pseudogenes (but not necessarily RPL36AP1) can modulate the expression of related genes through RNA-mediated mechanisms, sometimes affecting disease processes[2]. If a functional ribosomal protein (not a pseudogene) is intended, the related gene is **RPL36A (ribosomal protein L36a)**, which is a structural component of the large (60S) ribosomal subunit and has roles in protein synthesis, cell proliferation, and has been implicated in certain cancers[3][4][7].

Other names

RPL36A_19_1371RPL36A pseudogene 1RPL36AP1